ImmuPharma (LON:IMM) Trading Down 9.9% - Should You Sell?

Key Points

• ImmuPharma's share price fell by 9.9% on Wednesday, closing at GBX 10.90 ($0.15), following a significant increase in trading volume of 72% compared to the average session.
• The company reported a negative PE ratio of -1,224.72 and a projected earnings per share of -339.0000022 for the current year, indicating financial struggles.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price traded down 9.9% on Wednesday . The stock traded as low as GBX 10.58 ($0.14) and last traded at GBX 10.90 ($0.15). 14,800,078 shares were traded during trading, an increase of 72% from the average session volume of 8,597,301 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Price Performance

The firm has a 50-day simple moving average of GBX 4.84 and a two-hundred day simple moving average of GBX 3.44. The company has a market cap of £54.47 million, a PE ratio of -1,224.72 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.